Intravenous Calcitriol Therapy in an Early Stage Prevents Parathyroid Gland Growth

Overview

Journal Nephrol Dial Transplant

Publisher Oxford University Press

Specialties General Surgery
Nephrology

Date 2008 Jun 3

PMID 18515308

Citations 2

Authors

Masatomo Taniguchi

Masanori Tokumoto

Kazuhiko Tsuruya

Hideki Hirakata

Mitsuo Iida

Affiliations

Soon will be listed here.

Abstract

Background: Both the phenotypic alterations of parathyroid (PT) cells, e.g. down-regulation of the calcium-sensing receptor, and the increase of the PT cell number in nodular hyperplasia are the main causes of refractory secondary hyperparathyroidism. It is of great importance to prevent PT growth in an early stage.

Methods: To examine a more effective method of calcitriol therapy for the prevention of PT hyperplasia, we randomized haemodialysis patients with mild hyperparathyroidism to receive either daily orally administered calcitriol (n = 33) or intravenous calcitriol (n = 27) over a 12-month study period. Calcitriol was modulated so as to keep the serum intact PTH level between 100 and 150 pg/ml.

Results: Both groups showed similar reductions of the serum PTH level and similar increases in serum calcium. In both groups, there were no significant changes in the serum phosphate level. Long-term daily oral calcitriol therapy failed to prevent the increase of both maximum PT volume and total volume, as assessed by ultrasonography; however, intravenous calcitriol therapy successfully suppressed this progression. In the daily, oral group, both the bone-specific alkaline phosphatase (BAP) and the N-telopeptide cross-linked of type I collagen (NTX) significantly decreased, which was probably due to the PTH suppression. However, these bone metabolism markers remained stable in the intravenous group. The total dosage of calcitriol during the study was comparable in both groups.

Conclusions: These data indicate that intravenous calcitriol therapy in an early stage of secondary hyperparathyroidism is necessary to prevent PT growth and to keep a good condition of bone metabolism.

Citing Articles

Comparison of oral and intravenous alfacalcidol in chronic hemodialysis patients.

Lessard M, Ouimet D, LeBlanc M, Nadeau-Fredette A, Bell R, Lafrance J BMC Nephrol. 2014; 15:27.

PMID: 24495277 PMC: 3915223. DOI: 10.1186/1471-2369-15-27.

Vitamin D effects on pregnancy and the placenta.

Shin J, Choi M, Longtine M, Nelson D Placenta. 2010; 31(12):1027-34.

PMID: 20863562 PMC: 2993775. DOI: 10.1016/j.placenta.2010.08.015.

References

Halstead L, Scott M, Rifas L, Avioli L . Characterization of osteoblast-like cells from normal adult rat femoral trabecular bone. Calcif Tissue Int. 1992; 50(1):93-5. DOI: 10.1007/BF00297304. View

Liou H, Chiang S, Huang T, Shieh S, Akmal M . Comparative effect of oral or intravenous calcitriol on secondary hyperparathyroidism in chronic hemodialysis patients. Miner Electrolyte Metab. 1994; 20(3):97-102. View

Canaff L, Hendy G . Human calcium-sensing receptor gene. Vitamin D response elements in promoters P1 and P2 confer transcriptional responsiveness to 1,25-dihydroxyvitamin D. J Biol Chem. 2002; 277(33):30337-50. DOI: 10.1074/jbc.M201804200. View

Akiba T, Kurihara S, Yamada T, Ogasawara M, Yoneshima H, Marumo F . Intravenous calcitriol can increase bone mass in hemodialysis patients with osteitis fibrosa. Miner Electrolyte Metab. 1995; 21(1-3):109-13. View

Tominaga Y, Takagi H . Molecular genetics of hyperparathyroid disease. Curr Opin Nephrol Hypertens. 1996; 5(4):336-41. DOI: 10.1097/00041552-199607000-00008. View

Brown A, Zhong M, Finch J, Ritter C, McCracken R, Morrissey J . Rat calcium-sensing receptor is regulated by vitamin D but not by calcium. Am J Physiol. 1996; 270(3 Pt 2):F454-60. DOI: 10.1152/ajprenal.1996.270.3.F454. View

Taniguchi M, Tokumoto M, Matsuo D, Motoyama K, Sugitani A, Kuroki S . Persistent hyperparathyroidism in renal allograft recipients: vitamin D receptor, calcium-sensing receptor, and apoptosis. Kidney Int. 2006; 70(2):363-70. DOI: 10.1038/sj.ki.5001549. View

Lomri A, Marie P, Tran P, Hott M . Characterization of endosteal osteoblastic cells isolated from mouse caudal vertebrae. Bone. 1988; 9(3):165-75. DOI: 10.1016/8756-3282(88)90006-3. View

Reichel H, Szabo A, Uhl J, Pesian S, Schmutz A, Schmidt-Gayk H . Intermittent versus continuous administration of 1,25-dihydroxyvitamin D3 in experimental renal hyperparathyroidism. Kidney Int. 1993; 44(6):1259-65. DOI: 10.1038/ki.1993.377. View

10.

Peng S, Yang C, Ferng S, Chen L . A crossover comparison of intermittent oral and intravenous administration of calcitriol on the parathyroid hormone concentration in hemodialysis patients. Miner Electrolyte Metab. 1997; 23(1):13-8. View

11.

Szabo A, Merke J, Beier E, Mall G, Ritz E . 1,25(OH)2 vitamin D3 inhibits parathyroid cell proliferation in experimental uremia. Kidney Int. 1989; 35(4):1049-56. DOI: 10.1038/ki.1989.89. View

12.

Matsumoto T, Igarashi C, Takeuchi Y, Harada S, Kikuchi T, Yamato H . Stimulation by 1,25-dihydroxyvitamin D3 of in vitro mineralization induced by osteoblast-like MC3T3-E1 cells. Bone. 1991; 12(1):27-32. DOI: 10.1016/8756-3282(91)90051-j. View

13.

Andress D, Norris K, Coburn J, Slatopolsky E, Sherrard D . Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med. 1989; 321(5):274-9. DOI: 10.1056/NEJM198908033210502. View

14.

Manolagas S, Burton D, Deftos L . 1,25-Dihydroxyvitamin D3 stimulates the alkaline phosphatase activity of osteoblast-like cells. J Biol Chem. 1981; 256(14):7115-7. View

15.

Fukuda N, Tanaka H, Tominaga Y, Fukagawa M, Kurokawa K, Seino Y . Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest. 1993; 92(3):1436-43. PMC: 288288. DOI: 10.1172/JCI116720. View

16.

Taniguchi M, Tokumoto M, Matsuo D, Tsuruya K, Hirakata H, Iida M . Parathyroid growth and regression in experimental uremia. Kidney Int. 2006; 69(3):464-70. DOI: 10.1038/sj.ki.5000090. View

17.

Fischer E, Harris D . Comparison of intermittent oral and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism. Clin Nephrol. 1993; 40(4):216-20. View

18.

Quarles L, Yohay D, Carroll B, Spritzer C, Minda S, Bartholomay D . Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int. 1994; 45(6):1710-21. DOI: 10.1038/ki.1994.223. View

19.

Salusky I, Goodman W, Horst R, Segre G, Kim L, Norris K . Pharmacokinetics of calcitriol in continuous ambulatory and cycling peritoneal dialysis patients. Am J Kidney Dis. 1990; 16(2):126-32. DOI: 10.1016/s0272-6386(12)80566-x. View

20.

Fukagawa M, Kitaoka M, Yi H, Fukuda N, Matsumoto T, Ogata E . Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long-term prognosis of calcitriol pulse therapy in chronic dialysis patients. Nephron. 1994; 68(2):221-8. DOI: 10.1159/000188261. View